Even compared to other biopharmaceuticals, chimeric antigen receptor (CAR) T-cell therapies are particularly complex. Mass spectrometry (MS)–based process analytical technologies can be a powerful tool in identifying and monitoring key attributes throughout the manufacturing process.
